A Clinical Study to Evaluate the Safety and Pharmacokinetics of Topical RSS0393 Ointment in Children and Adolescents With Plaque Psoriasis

Exclusion Criteria

• •1. Diagnosis of psoriasis other than plaque at screening.
• •2. Subjects have other skin diseases or conditions that may affect the evaluation of the relevant endpoints of this study.
• •3. Subjects with any other persistent active autoimmune disease.
• •4. Subjects who have received topical medication for psoriasis within 14 days before baseline, or systemic medication or phototherapy for psoriasis within 28 days before baseline, or biological agents for psoriasis within a specified time before baseline.